Table 1.

Clinical characteristics of ovarian carcinoma patients, sequenced vs. not sequenced

CharacteristicsSequencedNot sequenced
N1,195678
Age
 <4040 (3.3%)23 (3.4%)
 40–49176 (14.7%)90 (13.3%)
 50–59385 (32.2%)221 (32.6%)
 60–69374 (31.3%)236 (34.8%)
 70–79205 (17.2%)91 (13.4%)
 ≥8015 (1.3%)17 (2.5%)
Race/ethnicitya
 Non-Hispanic White1,048 (87.7%)518 (76.4%)
 Hispanic51 (4.3%)23 (3.4%)
 Non-Hispanic Black46 (3.8%)34 (5.0%)
 Asian/Pacific Islander31 (2.6%)86 (12.7%)
 Other or unknown19 (1.6%)17 (2.5%)
Disease site
 Ovary998 (83.5%)565 (83.3%)
 Peritoneal171 (14.3%)103 (15.2%)
 Fallopian tube26 (2.2%)10 (1.5%)
Stagea
 III/Optimal465 (38.9%)175 (25.8%)
 III/Suboptimal453 (37.9%)299 (44.1%)
 IV277 (23.2%)204 (30.1%)
Histologyb
 HG Serous971 (81.3%)526 (77.6%)
 LG Serous46 (3.8%)25 (3.7%)
 Carcinoma, NS84 (6.2%)81 (14.2%)
 LG Endometrioid4 (0.3%)2 (0.3%)
 HG Endometrioid38 (3.2%)15 (2.2%)
 Clear cell28 (2.3%)27 (4.0%)
 Mucinous7 (0.6%)12 (1.8%)
Treatment
 CT + P → P408 (34.1%)217 (32.0%)
 CT + B → P386 (32.3%)239 (35.3%)
 CT + B → B401 (33.6%)222 (32.7%)
  • Abbreviations: HG, high-grade, grades 2 and 3; LG, low-grade, grade 1; NS, not specified; CT, chemotherapy; P, placebo; B, bevacizumab.

  • aP < 0.001, χ2.

  • bP = 0.012, χ2.